GRAL · XBRL financial data

GRAIL financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GRAL's year ends in late December)

In millions of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	32	29	38*	32	36	36	44*	41	45
Research and development	94	78	48*	54	47	49	47*	48	47
General and administrative	67	47	42*	45	38	37	39*	43	51
Operating income (loss)	(1,641)	(184)	(137)*	(154)	(159)	(125)	(124)*	(136)	(174)
Interest income	3	12	9*	8	7	6	8*	8	7
Other income (expense)	0	(1)	1*	(1)	(1)	0	(0)*	0	(0)
Income tax expense (benefit)	(53)	(47)	(30)*	(40)	(39)	(30)	(17)*	(34)	(56)
Net income (loss)	(1,585)	(126)	(97)*	(106)	(114)	(89)	(99)*	(93)	(110)
Earnings per share, basic USD per share	(51.06)	(3.94)	(2.89)*	(3.10)	(3.18)	(2.46)	(2.44)*	(2.29)	(2.56)
Earnings per share, diluted USD per share	(51.06)	(3.94)	(2.89)*	(3.10)	(3.18)	(2.46)	(2.44)*	(2.29)	(2.56)
Weighted average shares, basic millions of shares	31	32	34*	34	36	36	41*	41	43
Weighted average shares, diluted millions of shares	31	32	34*	34	36	36	41*	41	43

Fiscal quarters (GRAL's year ends in late December)

In millions of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	959	854	214	134	127	127	250	69	56
Accounts receivable	—	—	20	19	16	16	18	20	20
Prepaid and other current assets	21	20	17	15	13	15	15	17	16
Total current assets	1,019	910	820	728	652	589	954	877	915
Property and equipment, net	—	—	69	65	60	56	52	48	44
Right-of-use asset	75	71	66	62	60	56	52	48	89
Goodwill	0	0	0	—	—	—	—	—	—
Total assets	3,270	3,118	2,983	2,848	2,703	2,601	2,922	2,803	2,844
Accounts payable	—	—	5	6	6	3	2	5	7
Accrued liabilities	57	69	57	54	49	58	64	58	64
Total current liabilities	88	94	77	75	71	77	80	75	84
Lease liability, non-current	62	59	55	51	48	45	43	41	81
Total liabilities	575	530	480	434	388	361	344	303	301
Accumulated deficit	(9,581)	(9,706)	(9,803)	(9,910)	(10,024)	(10,113)	(10,212)	(10,305)	(10,415)
Total stockholders' equity	2,695	2,588	2,503	2,414	2,315	2,240	2,578	2,501	2,543
Total liabilities and equity	3,270	3,118	2,983	2,848	2,703	2,601	2,922	2,803	2,844
Common shares outstanding (cover page) millions of shares	31	34	34	36	36	39	41	43	45

Fiscal quarters (GRAL's year ends in late December)

In millions of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,585)	(126)	(97)*	(106)	(114)	(89)	(99)*	(93)	(110)
Stock-based compensation	26*	17*	14*	16	14*	14*	14*	17	20*
Net cash from operating activities	(172)*	(105)*	(93)*	(95)	(77)*	(63)*	(64)*	(87)	(81)*
Purchases of property and equipment	1*	1*	0*	0	0*	0*	0*	1	0*
Net cash from investing activities	(1)*	(1)*	(546)*	15	70*	67*	(237)*	(93)	(47)*
Net cash from financing activities	932*	0*	0*	0	0*	0*	423*	—	—
Net change in cash	759*	(105)*	(640)*	(80)	(6)*	3*	123*	(180)	(14)*

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
GRAIL	56	45	(81)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Veracyte	300	150	46*	80.4M	—	Q2 FY26 10-QJun 30, 2026
CareDx	250	139	13*	52.5M	—	Q3 FY26 10-QSep 30, 2026
Caris Life Sciences	not reported	264	28*	282.6M	—	Q2 FY26 10-QJun 30, 2026
RadNet	726	623	94*	78.7M	—	Q2 FY26 10-QJun 30, 2026
BillionToOne	549	109	9.1*	not reported	—	Q2 FY26 10-QJun 30, 2026
Guardant Health	1,053	335	(58)*	134.2M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Personalis	94	22	(26)*	106.8M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Castle Biosciences	62	104	15*	30.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.